Gain Therapeutics, Inc. announced the completion of dosing in the multiple ascending dose (MAD) of its Phase 1 study of GT-02287, a novel small molecule therapy for Parkinson's Disease.
AI Assistant
GAIN THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.